Precise
Precise\u2122 - a new advancement in autologous therapies

HOPKINTON, Mass., June 9, 2023 (Newswire.com) - Isto Biologics, a leader in orthobiologic regeneration technologies and cell-based therapies that focuses on helping patients heal faster, announced today the launch of Precise™, a brand-new, state-of-the-art technology that delivers a final PRP product with precision cellular fractions upon concentration.

The Precise system's CellectFlex™ Technology allows for tailored cell compositions with each spin, allowing the system to provide a targeted range of offerings that have never been available before.

"We are excited to introduce this novel addition to our line of autologous therapies," said Don Brown, Isto's Chief Executive Officer. "Precise offers physicians and surgeons the ability to customize their PRP to fit their patient needs."

The Precise system utilizes patented technology that offers solutions to obtain both leukocyte-poor and leukocyte-rich PRP outputs. In a single spin, Precise can deliver a low hematocrit and granulocyte count, all while delivering a high platelet and mononucleated cell concentrate.

"This exciting new product is a direct result of listening to the needs of our customers," said Brian Barnes, PhD, President at Isto Biologics. "We are in a constant pursuit to deliver products that change the lives of patients and believe that Precise will keep physician and patient needs front and center with no compromise."

Current Precise Offerings

Precise Sapphire - The Precise Sapphire kit will provide a leukocyte-rich PRP, with a final PRP output that equates to 'the perfect PRP' based on platelet concentration, mononucleated cells, granulocytes and hematocrit counts.

Precise Diamond - The Precise Diamond kit will provide a leukocyte-poor PRP and further reduces the inflammatory cell fractions being the neutrophils (granulocytes) and hematocrit all while capturing therapeutic concentrations of platelets (growth factors) and elevating mononucleated cells above baseline.

About Isto Biologics

Isto Biologics is a leading biologics and cellular therapy company in the orthopedic space. Isto Biologics is focused on Helping Patients Heal Faster™ through innovative solutions for bone regeneration and cell-based therapies. The company's flagship product offerings include the market-leading Magellan® Autologous Platelet Separator, and bone graft products including InQu® Bone Graft Extender & Substitute, and the Influx™ product family.

For more information, visit  istobiologics.com 

TAMPA, Fla., June 9, 2023 (Newswire.com) - Black Book Research announced that Waystar has been named the leading vendor for Revenue Cycle Management Software Technology for Large Hospitals & Academic Medical Centers as well as Health Systems, Chains, and IDNs, acknowledged by RCM solutions clients in the 2023 RCM survey responses of 1,902 hospital executives, financial system users, and business office leaders from 680 inpatient organizations.

From Q4 2022 through Q2 2023, the Black Book Research financial digital transformation software client/user survey investigated 307 finance functional category vendors utilized by a total of 5,895 validated client users for the solutions vendor ratings. 

In a marketplace of several hundred core and niche Revenue Cycle Management (RCM) solutions vendors, the current Black Book survey respondents evaluated healthcare provider technology tools. Waystar's business units, including Navicure, Zirmed, Recondo, Connance, Patientco and eSolutions, have been top-rated by customers in the Black Book annual survey processes for over a decade, with top client satisfaction ratings since 2012.

Waystar scored highest in 12 of 18 revenue cycle management key performance indicators, including Strategic Alignment of Client Goals; Innovation; Training; Trust, Transparency, Accountability; Breadth of offerings; Deployment and implementation; Customization; Brand image and marketing communications; Marginal value adds; Viability, Managerial Stability; Support and customer care; and Best of breed technology and process improvement.

Full results can be found at https://blackbookmarketresearch.com/finance-revenue-cycle-management.

Black Book conducts crowdsourced polls and surveys with healthcare executives and front-line users about their current technology trends, and services partners and awards top-performing vendors' recognition based on performance using indicators of client experience, loyalty, and customer satisfaction.

About Black Book

Black Book™, its founder, management, and staff do not own or hold any financial interest in any of the vendors covered and encompassed in the RCM surveys it conducts, including Waystar. Black Book reports the results of the collected satisfaction and client experience rankings in publication and to media prior to vendor notification of rating results and does not solicit vendor participation fees, review fees, inclusion or briefing charges, and/or vendor collaboration as Black Book polls vendors' clients.

For methodology, auditing, resources, comprehensive research, and ranking data, see www.blackbookmarketresearch.com or contact us at [email protected].

TRUMBULL, Conn., June 9, 2023 (Newswire.com) - The Orthobiologic Institute (TOBI) and The American Society of Interventional Pain Physicians (ASIPP) are set to host a highly anticipated CME activity that serves as a platform for physicians to acquire the latest scientific knowledge in the field of orthobiologics and regenerative medicine. Among the distinguished sponsors participating in this prestigious event is ZetrOz Systems, a leading company specializing in innovative pain relief medical devices. ZetrOz is excited to announce its presence at TOBI, where they will be showcasing their groundbreaking wireless wearable ultrasound device, the sam X1, aimed at revolutionizing the treatment of soft tissue injuries within the regenerative medicine market. 

The TOBI Conference is an annual CME activity that provides physicians with an unparalleled opportunity to stay up to date with the rapidly evolving field of orthobiologic and regenerative medicine. Renowned for its highly credentialed expert speakers and evidence-based presentations, TOBI has established itself as a premier gathering for professionals seeking to enhance their knowledge and skills in this specialized area of medicine. The conference serves as a gateway to the latest breakthroughs, research, and best practices, fostering collaboration and innovation within the industry. 

As one of the key sponsors of TOBI, ZetrOz is eager to feature their revolutionary device, the sam X1, to the distinguished attendees. The sam X1 is a wireless wearable ultrasound device designed to deliver targeted therapeutic treatment for soft tissue injuries. Harnessing advanced technology, this cutting-edge device holds the potential to transform the way medical professionals approach the healing process of various soft tissue conditions. 

With its portable and wireless capabilities, the sam X1 enables physicians to administer ultrasound therapy with unparalleled convenience and precision. By facilitating deep tissue healing, the device enhances the body's regenerative capacity, promoting accelerated recovery and improved patient outcomes. The sam X1 is poised to revolutionize the regenerative medicine market, offering an innovative solution that combines effectiveness, mobility, and patient comfort.

ZetrOz Systems can be found at booth #117, where they will be demonstrating the sam X1 to conference attendees, offering them an immersive experience of their pain relief device. Visitors will have the opportunity to engage with ZetrOz's team of experts, who will provide in-depth insights into the scientific principles behind the sam X1 and its potential applications. Through live demonstrations, informative presentations, and interactive discussions, the booth promises to be a focal point for physicians seeking to explore the latest technologies that can enhance their practice and advance patient care. 

The TOBI Conference stands as a pivotal event for physicians interested in the latest advancements in orthobiologic and regenerative medicine. ZetrOz's presence at TOBI highlights their commitment to innovation and patient-centric care and their ability to make a significant impact on the regenerative medicine market.

To learn more, visit www.samrecover.com.

About ZetrOZ Systems

ZetrOZ Systems is leading healing innovations in sports medicine, developing wearable bioelectronic devices for the delivery of sustained acoustic medicine (sam®). Researched and funded by the federal government, ZetrOZ is built on the proprietary medical technology of +46 patents and is the exclusive manufacturer and developer of the sam® product line, which is designed for the treatment of acute and chronic musculoskeletal conditions.